Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma

By sjmartinez • February 18, 2025

Carlson S, Lin TL, Larson SM. Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma. Immunotherapy. 2025 Feb 17:1-12. doi: 10.1080/1750743X.2025.2461987. Epub ahead of print. PMID: 39961649.

Tags: allogeneic CAR, BCMA, CAR, chimeric antigen receptor, Fellow, GPCR5D, Hematology/Oncology, Multiple myeloma, Publications

Related Posts

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab[...]

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi[...]